The news sweep Thursday 16 December

Alligator Bioscience announces study update and presents early results for ATOR-1017 which confirms data regarding biomarkers, safety and tolerability. Read more.

and Spark Therapeutics plans to expand the clinical development program to include both the US and Europe. Read more.

Medfield Diagnostics announces that clinical data is in place for verification of the instrument MD100 Strokefinder. Read more.

Cereno Scientific receives a first granted patent in the third patent family for CS1. Read more.

Corline Biomedicals event partner Cardium has initiated clinical trials with CHS-coated products in both North America and Europe. Read moreKardium also reports on the first treated patient in a clinical trial in the Czech Republic. Read more.

Ascelia Pharma receives FDA-approval of IND application for clinical study with Oncoral. Read more.

2cureX announces that the first hospital has joined IGNITE, the evaluation program of IndiTreat. Read more.

BICO has entered into an agreement to acquire Biosero, active in software for automated workflows and connected laboratory environments. Read moreIn light of this, BICO invites you to a telephone conference today. Read more.

SciBase receives an order for ten new Nevisense systems and electrodes corresponding to an order value of approximately 100 KUSD from Advanced Dermatology. Read more.

Zealand Pharma has recruited the last patient (last patient needed) needed for the interim analysis in the phase III study with Glepaglutide. Read more.

ADDvise Group requests a change in the terms of the company's secured bond loan through written procedure. Read more.

Gentian Diagnostics provides an update on its SARS Cov-2 project. Read moreThe company will present at DNB Nordic Healthcare Conference. Read more.

EQL Pharma appoints Anna Jonsson to new Chief Financial Officer. Read more.

Polymer Factory updates on trademark registration. Read more.

Coloplast informs about insider transactions. Read more.

GPX Medical publishes investor letters. Read more.

News received since yesterday lunch:

Alligator Bioscience and Aptevo Therapeutics announced joint publication in the peer-reviewed journal Nature Communications.. Read more.

Scandinavian Realheart has received final approval for listing on Nasdaq First North Growth Market. Read more.

FDA granted Calliditas Therapeutics accelerated approval for the treatment of patients with primary IgA nephritis at risk of rapid disease progression. Read more.

Cereno Scientific announced a repurchase of called warrants from European High Growth Opportunities Securitization Fund. Read more.

FDA has issued a request for further information to Camurus American licensees Braeburn regarding their updated New Drug Application (NDA) for Brixadi. Read more.

Targovax published issue results. Read moreThe company has also received research grants from Research Council of Norway of 9,8 million NOK. Read moreThey also reported on insider trading. Read more.

New research paper demonstrates the potential for “lab-on-chip” catalysis with Attanas technology. Read more.

Guard Therapeutics has appointed Michael Reusch to the Chief Medical Officer. Read more.

Sobi and Apellis Pharmaceuticals announced that European Commission approved Aspaveli. Read more.

WACKER and Corden Pharma has signed an agreement for lipid nanoparticle formulation. Read more.

MSD announced that European Commission approves Waxneuvance. Read more.

EMA has assigned CSL Behrings tranacogene dezaparvovec so-called accelerated assessment. Read more.

Preclinical data regarding tasquinimod which was presented at Ash 2021 are available at Active Biotechs homepage. Read more.

This morning's winner: Calliditas Therapeutics 56,1%, Nicoccino Holding 23,5%, Redwood Pharma 14,1%, Euris 12,8%, Spago Nanomedical 8,9%

This morning's losers: Camurus -15,8%, CS Medica -9,6%, Chordate Medical -6,8%, Aegirbio -6,5%, Asarina Pharma -6,3%

Index: OMXS30 2315 +0,97%, Healthcare +0,43%